SEC Comment Letter 0000000000-24-008074 to AEON Biopharma, Inc. (AEON) (CIK 0001837607) (AEON)

AEON Biopharma, Inc. (AEON) (CIK 0001837607)
Date: July 16, 2024 · CIK: 0001837607 · Accession: 0000000000-24-008074

View on Edgar

AI Filing Summary & Sentiment

Date

July 16, 2024

Author

Not clearly detected

Form

UPLOAD

Company

AEON Biopharma, Inc. (AEON) (CIK 0001837607)

Letter

July 16, 2024 Marc Forth Chief Executive Officer AEON Biopharma, Inc. 5 Park Plaza, Suite 1750 Irvine, CA 92614 Re:AEON Biopharma, Inc. Amendment No. 1 to Form 10-K for Fiscal Year Ended December 31, 2023 File No. 1-40021 Dear Marc Forth: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

July 16, 2024
Marc Forth
Chief Executive Officer
AEON Biopharma, Inc.
5 Park Plaza, Suite 1750
Irvine, CA 92614
Re:AEON Biopharma, Inc.
Amendment No. 1 to Form 10-K for Fiscal Year Ended December 31, 2023
File No. 1-40021
Dear Marc Forth:
            We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io